Global Systemic
Lupus Erythematous
SLE Drugs Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2015-2025
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune
system to mistakenly attack health body tissue. In SLE, body immune system can affect any part
of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as
malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis,
serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever,
Raynaud’s phenomenon, livedo reticularis, thrombosis, and myositis. It is also known as a
disease of flare-ups and remissions and can range from mild to life threatening severity. It is also
called as drug-induced lupus erythematosus due to common observation against drugs such as
isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE.
While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still
the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate
mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug
in SLE because of the multiple beneficial effects of this agent.
Systemic Lupus Erythematous (SLE) Drugs Market: Drivers & Restraints
Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high
prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major
drivers for global systemic erythematous drugs market are development of novel SLE therapies,
increasing availability of bio similar drugs and increasing support for emerging research areas for
new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment
as well as consistent research and development processes for novel drug molecules are
important drivers for global lupus erythematous market.
Report
Description
Report Description
Additionally, safety and quality of systemic lupus erythematous controlling therapy may
possibly be a challenge for the growth of the global systemic lupus erythematous drugs
market. Moreover, numerous public awareness programs targeted to increase awareness
levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has
been implementing various projects to increase central support for SLE research and
services to support people and families affected by SLE. However, serious side effectswith
steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and
stringent regulatory approvals for new treatment options with better levels of efficacy
and safety are obstructing the global systemic lupus erythematous drugs market.
Request for sample report: http://www.futuremarketinsights.com/reports/sample/repgb-1149
Systemic Lupus Erythematous (SLE) Drugs Market: Segmentation
The global systemic lupus erythematous drugs market is classified on the basis of
molecule and region.
Based on type of molecule, the global systemic lupus erythematous drugs market is
segmented into the following:
Corticosteroids
Prednisone
Cortisone
Hydrocortisone
Report
Description
Report Description
•Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Over-the-counter NSAIDs include
• Ibuprofen (Motrin)
• Naproxen (Naprosyn)
• Prescription versions include
• Indomethacin (Indocin)
• Nabumetone (RELAFEN)
• Celecoxib (Celebrex)
•Anti-Inflammatories
• Aspirin
• Acetaminophen (Tylenol)
•Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Hydroxychloroquine (Plaquenil).
• Cyclosporine (Gengraf, Neoral, Sandimmune)
• Azathioprine (Azasan, Imuran)
•Antimalarials
• Chloroquine (Aralen)
• Hydroxychloroquine (Plaquenil)
Report
Description
Report Description
BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
Belimumab (Benlysta)
Immunosuppressive Agents/Immune Modulators
Azathioprine (Imuran)
Methotrexate (Rheumatrex)
Cyclophosphamide (Cytoxan)
Anticoagulants
Low-dose aspirin
Heparin (Calciparine, Liquaemin)
Warfarin (Coumadin)
Systemic Lupus Erythematous (SLE) Drugs Market: Overview
Global systemic lupus erythematous drugs market growth is fast in North American region and is
estimated to project remarkable CAGR growth throughout forecast period. In North America,
the SLE is more prevalent among Hispanics, Asians, and Native Americans according to Centers
for Disease Control and Prevention (CDC). The second largest and fastest growing global
systemic lupus erythematous drugs market is Europe and is projected to reach nearly US$ 550
Mn and register a double digit CAGR due to higher prevalence of SLE in Europe. Among the
European countries Sweden, Iceland, Spain had the highest prevalence according to Lupus
Journal article, published in 2006. A drug called hydroxychloroquine being the last drug was
approved by FDA in 1955 for SLE treatment.
Report
Description
Report Description
Recently, a drug called belimumab has been approved by FDA after 50 years long gap specifically
for SLE on March 9, 2011. It is the first ever targeted biological drug for the treatment of SLE
patients developed by Human Genome Sciences Inc. in collaboration with GlaxoSmithKline. It
will be the primary driver for global systemic lupus erythematous drugs market growth in the
US, France, Germany, Italy Spain, the UK and Japan. Benlysta will lead market sales in coming
years because of its excellent safety profile as well as proven efficacy in clinical trials. NSAIDS
such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE.
Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral
(Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE
treatment. Additionally, the entry of four first-in-class (FIC) biologics such as Bristol-Myers
Squibb’s Orencia (abatacept), atacicept, epratuzumab and LY2127399 are anticipated to show a
major role in the expansion of the global systemic lupus erythematous drugs market.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1149
Systemic Lupus Erythematous (SLE) Drugs Market: Key Players
The global systemic lupus erythematous drugs market key players are Anthera
Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics,
Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705